Recombinant human growth hormone (r-hGH) treatment can optimise growth potential; however, optimum outcomes are not always achieved owing to several reasons, including poor adherence.
Atlantis Health co-authored co-authored a poster that was presented at the 2018 European Society for Paediatric Endocrinology conference, identifying key psychosocial factors and interventions to address these barriers through personalised behavioural patient-support programmes.